A Phase 3 interventional study of Liso-cel and Idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Withdrawn at 48 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb — 1 open to participants now, 3 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Bristol-Myers Squibb.
Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 3, and was the 24th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 6 · Phase 3 3
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 47 across the 21 interventional studies, 209 across the 4 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
2 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT03331198Juno Therapeutics, a Subsidiary of CelgeneStudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | 2027-11-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed treatment with both BTKi and BCL2i targeted therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Other reasons include:.
i) Having certain treatments in the past.
ii) Having certain infections that are not under control.
iii) Having certain brain conditions.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Liso-cel · Drug: Fludarabine · Drug: Cyclophosphamide
Drug: Idelalisib · Drug: Rituximab · Drug: Bendamustine
Specified dose on specified days
Also known as: JCAR017, Breyanzi®, BMS-986387, lisocabtagene maraleucel
Specified dose on specified days
Also known as: Zydelig®
Specified dose on specified days
Also known as: Rituxan®, Mabthera®, Riximyo®, Truxima®
Specified dose on specified days
Also known as: Bendeka®, Treanda®, Belrapzo®
Specified dose on specified days
Also known as: Fludara®, Bendarabin®
Specified dose on specified days
Also known as: Endoxan®, Cytoxan®
Progression Free Survival (PFS) per independent review committee (IRC) assessment
Time frame: Up to 5 years from the last participant randomized
Overall Survival (OS)
Time frame: Up to 5 years from the last participant randomized
Complete Response Rate (CRR) per IRC assessment
Time frame: Up to 5 years from the last participant randomized
CRR per investigators' assessment
Time frame: Up to 5 years from the last participant randomized
Complete response with incomplete bone marrow recovery (CRi)
Time frame: Up to 5 years from the last participant randomized
Minimal residual disease (MRD)-negativity rate
Time frame: Up to 5 years from the last participant randomized
Overall Response Rate (ORR) per IRC assessment
Time frame: Up to 5 years from the last participant randomized
ORR per investigators' assessment
Time frame: Up to 5 years from the last participant randomized
Duration of Response (DOR) per IRC assessment
Time frame: Up to 5 years from the last participant randomized
Duration of Complete Response (DOCR) per IRC assessment
Time frame: Up to 5 years from the last participant randomized
PFS per investigators' assessment
Time frame: Up to 5 years from the last participant randomized
Progression post next line of treatment (PFS-2)
Time frame: Up to 5 years from the last participant randomized
Number of participants with Adverse Events (AEs)
Time frame: Up to 5 years from the last participant randomized
Number of participants with Adverse Events of Special Interest (AESIs)
Time frame: Up to 5 years from the last participant randomized
Number of participants with laboratory abnormalities
Time frame: Up to 5 years from the last participant randomized
Time from randomization to first confirmed clinically meaningful improvement from baseline in the European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30)
The following domains on the EORTC QLQ-C30 will be assessed: * Fatigue * Physical functioning * Role functioning * Cognitive functioning * Global health status/quality of life (GHS/QoL)
Time frame: Up to 5 years from the last participant randomized
Time from randomization to first confirmed clinically meaningful improvement from baseline in the European Quality of Life Module Chronic Lymphocytic Leukemia 17 (EORTC QLQ-CLL17)
The following domains on the EORTC QLQ-CLL17 will be assessed: * Symptom burden * Physical condition/fatigue
Time frame: Up to 5 years from the last participant randomized
Mean changes from baseline in the following key health-related quality of life (HRQoL) domains: GHS/QoL
As assessed by EORTC QLQ-C30
Time frame: Up to 5 years from the last participant randomized
Mean changes from baseline in the following key HRQoL domains: Fatigue
As assessed by EORTC QLQ-C30
Time frame: Up to 5 years from the last participant randomized
Mean changes from baseline in the following key HRQoL domains: Physical functioning
As assessed by EORTC QLQ-C30
Time frame: Up to 5 years from the last participant randomized
Mean changes from baseline in the following key HRQoL domains: Role functioning
As assessed by EORTC QLQ-C30
Time frame: Up to 5 years from the last participant randomized
Mean changes from baseline in the following key HRQoL domains: Cognitive functioning
As assessed by EORTC QLQ-C30
Time frame: Up to 5 years from the last participant randomized
Mean changes from baseline in the following key HRQoL domains: Symptom burden
As assessed by EORTC QLQ-CLL17
Time frame: Up to 5 years from the last participant randomized
Mean changes from baseline in the following key HRQoL domains: Physical condition/fatigue
As assessed by EORTC QLQ-CLL17
Time frame: Up to 5 years from the last participant randomized
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Start is estimated for Jan 2024; primary completion for Oct 2031, 92 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisocabtagene maraleucel
Leukemia, Lymphocytic, Chronic, B-Cell →
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company →